ArticleHepatology communications2020

Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma.

Won-Mook Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.